Please use this identifier to cite or link to this item: http://essuir.sumdu.edu.ua/handle/123456789/44312
Or use following links to share this resource in social networks: Recommend this item
Title Pro-inflammatory S100A9 protein as a robust biomarker differentiating early stages of cognitive impairment in Alzheimer’s Diseased
Authors Horvath, Istvan
Jia, Xueen
Per, Johansson
Wang, Chao
Moskalenko, Roman Andriiovych  
Steinau, Andreas
Forsgren, Lars
Wagberg, Thomas
Svensson, Johan
Zetterberg, Henrik
Morozova-Roche, Ludmilla
Keywords Хвороба Альцгеймера
Болезнь Альцгеймера
Alzheimer’s disease
ліквор
ликвор
cerebrospinal fluid
S100A9
біомаркери
биомаркеры
biomarkers
амілоїд
амилоид
amyloid
запалення
воспаление
inflammation
Type Article
Date of Issue 2016
URI http://essuir.sumdu.edu.ua/handle/123456789/44312
Publisher American Chemical Society
License
Citation Pro-inflammatory S100A9 Protein as a Robust Biomarker Differentiating Early Stages of Cognitive Impairment in Alzheimer’s Disease [Текст] / I. Horvath, X. Jia, Per J. et al. // ACS Chem Neurosci. 2016 Jan 20;7(1):34-9. doi: 10.1021/acschemneuro.5b00265. Epub 2015 Nov 12
Abstract Pro-inflammatory protein S100A9 was established as a biomarker of dementia progression and compared with others such as Aβ1−42and tau-proteins. CSF samples from 104 stringently diagnosed individuals divided into five subgroups were analyzed, including nondemented controls, stable mild cognitive impairment (SMCI), mild cognitive impairment due to Alzheimer’s disease (MCI-AD), Alzheimer’s disease (AD), and vascular dementia (VaD) patients. ELISA, dot-blotting, and electrochemical impedance spectroscopy were used as research methods. The S100A9 and Aβ1−42 levels correlated with each other: their CSF content decreased already at the SMCI stage and declined further under MCIAD, AD, and VaD conditions. Immunohistochemical analysis also revealed involvement of both Aβ1−42 and S100A9 in the amyloid-neuroinflammatory cascade already during SMCI. Tau proteins were not yet altered in SMCI; however their contents increased during MCI-AD and AD, diagnosing later dementia stages. Thus, four biomarkers together, reflecting different underlying pathological causes, can accurately differentiate dementia progression and also distinguish AD from VaD
Appears in Collections: Наукові видання (МІ)

Views

Canada Canada
2
China China
1
France France
4
Germany Germany
6
Italy Italy
1
Japan Japan
2
Netherlands Netherlands
1
Peru Peru
1
Poland Poland
4
Portugal Portugal
1
Russia Russia
1
South Korea South Korea
2
Ukraine Ukraine
207
United States United States
4
Unknown Country Unknown Country
18

Downloads

Bosnia and Herzegovina Bosnia and Herzegovina
1
China China
9
Ecuador Ecuador
1
France France
1
Germany Germany
8
Indonesia Indonesia
1
Italy Italy
1
Japan Japan
3
Libya Libya
1
Morocco Morocco
1
Nigeria Nigeria
1
Norway Norway
1
South Korea South Korea
1
Ukraine Ukraine
160
United States United States
76
Unknown Country Unknown Country
154

Files

File Size Format Downloads
ACS_Chem_Neurosci.pdf 4,47 MB Adobe PDF 420

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.